Business, energy, technology, markets and global industry news from Business News Today

ER-positive breast cancer

PharmaDeviceNews ER-positive breast cancer
Representative image of an oncology consultation, illustrating how Roche and Genentech’s giredestrant FDA priority review could reshape endocrine therapy decisions in early-stage breast cancer.
Pharma & Biotech

Roche’s giredestrant FDA review raises the stakes in adjuvant breast cancer treatment

Find out how Roche’s giredestrant FDA priority review could reshape endocrine therapy in early breast cancer.

Read More
Representative image showing a modern breast cancer consultation as Menarini’s elacestrant and capivasertib data raise fresh questions about oral targeted therapy in metastatic disease.
Pharma & Biotech

Menarini’s ASCO 2026 ELEVATE data raise bigger question on oral oncology combinations

Menarini’s elacestrant strategy is shifting from monotherapy to combinations. Can ELEVATE data support a broader breast cancer role?

Read More
Representative image of advanced breast cancer research, reflecting Menarini Group’s ASCO 2026 elacestrant data and the growing focus on targeted treatment combinations for ER-positive, HER2-negative metastatic breast cancer.
Pharma & Biotech

ASCO 2026: Menarini’s elacestrant program expands the fight against endocrine resistance

Find out how Menarini’s elacestrant data at ASCO 2026 could reshape ER-positive metastatic breast cancer treatment.

Read More